Resources from the same session
LBA29 - Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Presenter: Isabelle Ray-Coquard
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
517O - Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Presenter: Paul DiSilvestro
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
518O - Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
Presenter: Amit Oza
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA30 - Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)
Presenter: Jean Emmanuel Kurtz
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA31 - Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial
Presenter: Keiichi Fujiwara
Session: Proffered Paper session: Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA30 and LBA31
Presenter: Mansoor Raza Mirza
Session: Proffered Paper session: Gynaecological cancers
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Gynaecological cancers
Resources:
Webcast